

ACR Convergence 2022

12S142. Abstracts: Spondyloarthritis Including PsA – Treatment I: Axial Spondyloarthritis (0542–0547)

0547. Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF Blockers.

Presented by Lars Rogge, Immunologist, Institut Pasteur, Paris.

This was a very technical presentation looking at which T cell populations express genes associated with SpA susceptibility, and trying to understand how anti-TNF and IL-17A blockers therapies work.

The study showed that the two currently used biotherapies of axSpA act by strikingly distinct cellular and molecular mechanisms. While anti-TNF therapy has major effects on systemic immune responses with potential implications for increased susceptibility to infectious microorganisms, IL-17 inhibitors had a lesser impact on systemic immune responses compared to TNFi, suggesting that they may rather act on non-immune cells and/or in inflamed tissues.

Understanding how these therapies work is a priority for optimal clinical care and reducing healthcare costs.